Advertisement
Research Article
01 August 2009

Characterization of a Novel ADAM Protease Expressed by Pneumocystis carinii

ABSTRACT

Pneumocystis species are opportunistic fungal pathogens that cause severe pneumonia in immunocompromised hosts. Recent evidence has suggested that unidentified proteases are involved in Pneumocystis life cycle regulation. Proteolytically active ADAM (named for “a disintegrin and metalloprotease”) family molecules have been identified in some fungal organisms, such as Aspergillus fumigatus and Schizosaccharomyces pombe, and some have been shown to participate in life cycle regulation. Accordingly, we sought to characterize ADAM-like molecules in the fungal opportunistic pathogen, Pneumocystis carinii (PcADAM). After an in silico search of the P. carinii genomic sequencing project identified a 329-bp partial sequence with homology to known ADAM proteins, the full-length PcADAM sequence was obtained by PCR extension cloning, yielding a final coding sequence of 1,650 bp. Sequence analysis detected the presence of a typical ADAM catalytic active site (HEXXHXXGXXHD). Expression of PcADAM over the Pneumocystis life cycle was analyzed by Northern blot. Southern and contour-clamped homogenous electronic field blot analysis demonstrated its presence in the P. carinii genome. Expression of PcADAM was observed to be increased in Pneumocystis cysts compared to trophic forms. The full-length gene was subsequently cloned and heterologously expressed in Saccharomyces cerevisiae. Purified PcADAMp protein was proteolytically active in casein zymography, requiring divalent zinc. Furthermore, native PcADAMp extracted directly from freshly isolated Pneumocystis organisms also exhibited protease activity. This is the first report of protease activity attributable to a specific, characterized protein in the clinically important opportunistic fungal pathogen Pneumocystis.
Members of the genus Pneumocystis are opportunistic fungal pathogens that infect immunocompromised mammalian hosts causing life-threatening pneumonia. Despite available therapies, the mortality from Pneumocystis pneumonia in humans remains high, ranging from 10 to 40% (14, 42). Treatment and prophylaxis failures have been demonstrated and emerging evidence indicates the development of drug resistance to the most commonly used antimicrobial agents (11, 12, 31). Due to the severity of Pneumocystis pneumonia, further investigations of this organism are warranted to develop new potential targets for therapy. Proteases represent one such potential therapeutic target. In other biological pathogens, drug targeting of proteases has proven a successful strategy (10).
In addition, further evidence suggests that proteases are involved in regulation of the life cycle of P. carinii (4). Although Pneumocystis cannot be continuously cultured in vitro, the protease inhibitor leupeptin has been shown to inhibit Pneumocystis in short-term proliferation assays, while another protease inhibitor aprotinin was demonstrated to enhance short-term organism growth (4, 39). These data provide intriguing indirect evidence that proteases are likely involved in regulating the organisms' life cycle. In addition, proteases are recognized as virulence factors in a number of microorganisms (10). Unfortunately, specific knowledge of proteases in Pneumocystis is fairly limited. Although homologues to the subtilisin clan of the serine protease family (PRT1 and KEX1) have been characterized in Pneumocystis, definitive protease function has not yet been demonstrated for these specific proteases (1, 15, 20, 22, 28, 29, 43).
A recent report of a proteolytically active ADAM (a disintegrin and metalloprotease) homologue in A. fumigatus has raised the possibility of the presence of ADAM homologues in other pathogenic fungi, particularly Pneumocystis species (21). ADAM proteins are membrane-anchored cell surface proteins that are structurally related to snake venom disintegrins (44). ADAM proteins possess a metalloprotease domain. When active, the metalloprotease domain has a shared consensus sequence HEXXHXXGXXHD (5). ADAM protease activities have also been demonstrated to a wide variety of target proteins (44). Furthermore, the ADAM protein mde10 in Schizosaccharomyces pombe has been demonstrated to play a role in the regulation of spore formation (32). An initial search of the P. carinii genomic sequencing project (http://pgp.cchmc.org/) yielded a 329-bp partial sequence with homology to known ADAM proteins. Accordingly, we sought to fully clone, characterize, and assess function of this novel Pneumocystis protein. Characterization of this molecule should provide additional important information about an important protease, with potential activity in Pneumocystis life cycle regulation and pathogenicity.

MATERIALS AND METHODS

Strains and organisms.

All animal studies were approved by the Mayo Institutional Animal Care and Utilization Committee. P. carinii organisms were originally derived from the American Type Culture Collection (ATCC; Rockville, MD) and maintained in immunosuppressed rats as we previously described (19). Female Long Evans rats (Harlan, Inc., Indianapolis, IN) were provided with dexamethasone (American Regent, Shirley, NY) at 1.2 mg/liter in their drinking water to induce immunosuppression. Antibiotics were simultaneously administered to avoid bacterial infection, specifically administering ampicillin (DAVA Pharmaceuticals, Fort Lee, NJ) at 500 mg/liter or cephalexin (Ranbaxy, India) at 500 mg/liter to the drinking water during alternate months (13). After 5 days, rats were anesthetized and intratracheally inoculated with P. carinii (∼106 total P. carinii nuclei). Pneumocystis pneumonia developed over 8 to 10 weeks, and the animals were sacrificed. Lungs were harvested, minced, and homogenized in a Stomacher Tissue Blender (Tekmar, Inc., Cincinnati, OH) in phosphate-buffered saline (PBS; pH 7.3). Homogenates were strained through sterile gauze and then examined by cytopreparation smears. Bacterial or fungal contaminated samples were discarded. Samples were centrifuged in Beckman J2-MC centrifuge at 4,960 × g for 10 min at 4°C, and the supernatants were discarded. Red blood cells were lysed by using distilled deionized water, and cells were resuspended in PBS (pH 7.3) and centrifuged as described above. The cellular pellets were resuspended, and homogenates were passed through a 10-μm-pore-size filter (Millipore, Inc., Billerica, MA) (24). When applicable, cyst and trophic forms were separated by a subsequent passage through 3-μm-pore-size filters (Millipore) as we previously reported For experiments requiring separation of the cysts and trophic forms, differential filtration through a 3-μm-pore-size filter was performed as we reported (41). Such filtration resulted in 99.5% pure trophic forms, which pass through the filter. The cysts are retained by the filter and provide a population that is >40-fold-enriched for cysts. The P. carinii forms were then either processed immediately for further analysis or flash frozen in a dry ice-methanol bath and stored at −80°C (41).

Identification of a Pneumocystis ADAM-like gene.

In order to identify molecules with potential protease characteristics, an in silico search of the P. carinii genome database (http://pgp.cchmc.org/) was performed using available sequences from ADAM-like molecules present in other fungi (38). Through this search, a 329-bp partial sequence was identified with homology to ADAM proteins known for protease and binding properties. The full-length sequence was obtained by using rapid amplification of cDNA ends (GeneRacer kit; Invitrogen) to obtain the remainder of the 5′ and 3′ coding sequences, employing gene specific antisense primers and methods we previously reported (19). This procedure yielded a final coding sequence of 1,650-bp for the putative P. carinii ADAM-like gene (PcADAM).

Sequence analysis.

MacVector 8.1.1 (Accelrys, Inc., San Diego, CA) was used to analyze the identified sequence and to predict protein size, antigenic sites, restriction enzyme sites, and protein alignments. The National Center for Biotechnology Information Basic Local Alignment Search Tool (BLAST) was used to identify protein homologues.

Molecular cloning of PcADAM.

The primers 5′-ATGCAATATCTATT-CAAATATATGA-3′ and 5′-TTACTCGCATACTGAACCTTTT-3′ were then used to create a complete 1,650-bp amplicon of the entire coding sequence using Taq DNA polymerase (Invitrogen, Inc., Carlsbad, CA) under the following conditions over 25 cycles: 2 min at 94°C (hot start); 15 s (s) at 94°C, 30 s at 55°C, and 2 min at 72°C; with a final 15 min at 72°C. Gel electrophoresis confirmed an amplicon of ∼1,650-bp. The PCR product was then cloned into the pYES2.1/V5-His-TOPO vector (Invitrogen) into TOP10F′ OneShot Escherichia coli cells (Invitrogen) using the TOPO cloning protocol according to the manufacturer's instructions. Sequences were confirmed, and plasmids were purified by using the QIAprep spin procedure (Qiagen, Valencia, CA). Haploid Saccharomyces cerevisiae strain BY4741 (ATCC 201388; ATCC, Manassas, VA) and strain BY4741 (ATCC 201388) (MATahis3delta1 leu2delta0 met15delta0 ura3delta0) were transformed with the plasmid clones as previously described (19).

Southern and chromosomal hybridization of PcADAM.

To verify that the PCR product was of P. carinii origin, a radiolabeled PcADAM amplicon was hybridized both to digested P. carinii genomic DNA and separated P. carinii chromosomes. Taq DNA polymerase (Invitrogen) was used with 5′-CGAATCATGTAAAAATGAATCA-3′ and 5′-CAACCTTTTTCTCCTCCACA-3′ primers to create a 276-bp probe by PCR. Probes were radioactively labeled with [α-32P]dATP (GE Healthcare, Inc., Piscataway, NJ) by using the RadPrime DNA labeling system (Invitrogen). Radioactively labeled probes were purified by using QuickSpin columns (Roche, Basel, Switzerland). The ExpressHyb protocol (Clontech Laboratories, Inc., Mountain View, CA) was then used for PcADAM probe hybridization to Pneumocystis chromosomal contour-clamped homogenous electronic field (CHEF) nitrocellulose membranes (a gift from Melanie Cushion). Hybridized membranes were placed on Kodak Biomax film and incubated at −70°C for development.
In a parallel fashion, Pneumocystis DNA was isolated by using the IsoQuick nucleic acid extraction system (Orca Research, Inc., Bothell, WA) and incubated with the endonucleases EcoRI, BamHI, and XbaI (Invitrogen). For comparison, rat genomic DNA was also digested with EcoRI. DNA was separated on a 1% agarose gel and transferred to nitrocellulose membranes. Radioactively labeled probes were created, hybridized, and imaged as described above. To verify RNA loading, we reprobed the membrane with a Pneumocystis β-actin probe (19).

Assessment of PcADAM mRNA expression over the life cycle of Pneumocystis.

RNA samples from separated Pneumocystis cyst and trophic forms were isolated by using the TRIzol reagent protocol (Invitrogen). Equal quantities (10 μg) of each were separated by electrophoresis through a 1% agarose gel with 30% formaldehyde. UV visualization of rRNA components was used to confirm equal nucleic acid loading. The RNA species were transferred to nitrocellulose. Radiolabeled probes were created, hybridized, and imaged as described. All findings were confirmed on at least three occasions.

Localization of PcADAMp protein in Pneumocystis life cycle forms.

We next sought to determine the relative extent of expression of the PcADAMp protein in Pneumocystis life cycle forms. Custom-made antibodies were generated to the synthetic peptides SNKPPKTLRKRSNLYL (Ab1) and IDRNNHRVYRGDAFVT (Ab2) (Bethyl Laboratories, Montgomery, TX) predicted from the translated PcADAM open reading frame. Immunoelectron microscopy was performed with these antibodies to identify the subcellular localization of the PcADAMp protein in separated life cycle forms of the organism (33). Pneumocystis cyst and trophic forms were separated by differential filtration and fixed in 4% formaldehyde and 0.2% glutaraldehyde in phosphate buffer for 16 to 24 h. After fixation, the specimens were rinsed in phosphate buffer and then dehydrated in a series of graded ethyl alcohol solutions while progressively lowering the temperature to −20°C. Briefly, the specimen was treated in 60% ethanol for 15 min at 4°C, in 70% ethanol for 60 min while lowering the temperature to −20°C, in 80% for 60 min at −20°C, 95% for 60 min, and finally in absolute alcohol for 60 min and then infiltrated in 1:1 ethanol-LR White resin overnight, exposed to fresh LR White resin for 60 min, and brought to room temperature and embedded in LR White resin. Specimens were polymerized at 55°C over 2 to 3 days. Thin sections (5 μm) were generated and mounted on nickel grids and dried overnight. Nonspecific binding sites were blocked first in aqueous 1% glycine solution then in PBS and 0.05% Tween 20 (PBST) with 1% normal serum. The antibody was diluted (1:10) in PBST with 1% normal serum, and sections were incubated in primary antibody (100 μg/ml) for 2 h at room temperature. Grids were next rinsed in PBST and incubated for 60 min with goat anti-rabbit immunoglobulin conjugated to 10-nm colloidal gold (33). After incubation, the grids were rinsed thoroughly in PBST and water and stained with uranyl lead. The sections were washed again and examined on a transmission electron microscope (model 6400; JEOL USA, Inc., Peabody, MA). During the immunoelectron condition, in excess of 100 Pneumocystis forms were examined by electron microsopy for deposition of gold particles and representative fields were photographed.

Expression of the PcADAMp protease.

Subsequently, heterologous expression of the putative PcADAMp protease was performed in yeast. S. cerevisiae containing PcADAM in pYES2.1/V5-His-TOPO was grown in URA minimal medium containing 2% glucose, and the expression of PcADAMp was induced in URA minimal medium with 2% galactose. Yeast cells were lysed by using the YPER reagent (Pierce Chemical Co., Rockford, IL) and a French press. The expressed protein was purified over a nickel affinity column (Pierce) and dialyzed against Tris-buffered saline (Pierce). Expression of the protein was confirmed with Western blotting. Protein concentrations were determined by using the Coomassie protein assay reagent protocol (Pierce), and the products were stored in 40% glycerol. In some applications, protease inhibitors were use,d including EDTA (20 mM), phenylmethylsulfonyl fluoride (2 mM), and Complete Mini-Protease cocktail (Roche Applied Science, Indianapolis, IN) dissolved in YPER lysis reagent.

Determination of Pneumocystis PcADAMp proteolytic activity.

We next performed zymography to evaluate whether PcADAMp exhibited protease activity. First, zymography was performed using PcADAMp expressed heterologously in yeast. To accomplish this, S. cerevisiae was induced to express PcADAMp as described above. The yeast cells were lysed using YPER reagent (Pierce), and the lysates were purified over a nickel affinity column. Samples were resuspended in zymogram sample buffer (Bio-Rad, Inc., Hercules, CA), and proteins were separated on 12% casein zymography gels (Bio-Rad) at 100 V. The gels were then incubated in reactivation buffer containing Zn2+, previously described to be required for ADAM metalloprotease activity (50 mM Tris, 200 mM NaCl2, 5 mM CaCl2, 0.5 mM ZnCl2), at pH 7.48, over 2 h to allow protein digestion to occur. The zymograms were rinsed, fixed, and stained with Coomassie blue R-250 (Bio-Rad). To further assess the need for the essential divalent Zn2+, additional zymography was performed in parallel in the absence of Zn2+.
In addition, we also assessed the proteolytic activity of native PcADAMp. To address this, P. carinii organisms were harvested from infected rat lungs. The organisms were incubated with lyticase (1 mg/ml; Sigma Chemical Co., St. Louis, MO) and lysed using YPER reagent (Pierce), followed by incubation with DNase I (1 mg/ml; Sigma). Next, the lysates were incubated with custom-made antibodies to PcADAMp (100 μg/ml each; Bethyl Laboratories), and protein A (Sigma) was used to immunoprecipitate the PcADAMp protease by using previously described methods (18). These samples were resuspended in zymogram sample buffer (Bio-Rad), and proteins were separated on 12% casein zymography gels (Bio-Rad) at 100 V. The gels were then incubated in reactivation buffer (50 mM Tris, 200 mM NaCl2, 5 mM CaCl2, 0.5 mM ZnCl2) at pH 7.48, over 2 h to allow protein digestion. Again, the zymograms were rinsed, fixed, and stained with Coomassie blue R-250 (Bio-Rad).

GenBank accession number.

Sequence data are available from GenBank under accession number EF025111.

RESULTS

P. carinii contains a putative ADAM-like gene, PcADAM.

After initial identification of a partial sequence encoding a possible ADAM-like protease in P. carinii, we proceeded to characterize the remainder of the coding sequence of the molecule. The complete sequence to PcADAM is shown in Fig. 1A (GenBank accession no. EF025111). The sequence predicts a conserved signal peptide, prodomain, metalloprotease domain, and partially conserved disintegrin domain. Interestingly, both the cysteine-rich and transmembrane domains often present in ADAM family molecules were absent. Significantly, the metalloprotease domain was found to contain a conserved zinc-binding catalytic site HEXXHXXGXXHD (Fig. 1B). Upstream of the metalloprotease domain, an RGD sequence was also present. The PcADAM revealed substantial homologies to previously reported ADAM family molecules using CLUSTAL W analysis, including a well-conserved metalloprotease domain, and a truncated disintegrin domain (Fig. 2).

Characterization of the PcADAM sequence in Pneumocystis.

Steps were next undertaken to characterize that PcADAM sequence within Pneumocystis and to verify that the PCR products were not related to amplification of any host cell contamination. First, a PcADAM 276-bp radiolabeled probe was hybridized to restriction endonuclease-digested Pneumocystis DNA, revealing a single band, suggesting a single-copy gene (Fig. 3A). The PcADAM probe did not hybridize to rat lung (host cell) DNA, further confirming the specificity of our amplicon. We have further probed both the Pneumocystis genomic DNA, and the rat lung DNA with rat GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a housekeeping gene, verifying the integrity of the DNA used in the rat controls (see Fig. SA in the supplemental material). In addition, the 276-bp PcADAM radiolabeled probe was demonstrated to hybridize to a single chromosome on a CHEF blot of separated P. carinii chromosomes (provided by Melanie Cushion, University of Cincinnati), confirming the presence of PcADAM within the Pneumocystis genome (Fig. 3B).

PcADAM is differentially expressed over the organism's life cycle.

To further address the relative expression of PcADAM in various Pneumocystis life cycle forms, freshly prepared organisms were fractionated by differential filtration into separated cyst and trophic life forms. RNA was extracted, separated through a 1.2% agarose gel in the presence of 2.2 M formaldehyde, and transferred to nitrocellulose. Northern blotting with the PcADAM probe demonstrated increased expression of PcADAM RNA in the cyst forms compared to the trophic forms (Fig. 4). To verify RNA loading, we reprobed the membrane with a Pneumocystis actin probe and confirmed that the equal loading and integrity of the RNA used in this analysis.
To further evaluate the regional distribution of the putative PcADAMp protease, synthetic peptide antibodies were generated against predicted sequences in the translated product and used for immunoelectron microscopy of purified Pneumocystis organisms. This analysis also demonstrated consistent labeling of cystic forms and far less abundant labeling of trophic forms (Fig. 5). The putative PcADAMp protease was largely present associated with the surface membrane, as well as with the intracystic bodies present inside of the mature cystic forms. Parallel immunoelectron microscopy studies performed simultaneously with an irrelevant antibody (recognizing PCRan1p) exhibited a completely different pattern of immune reactivity (7).

PcADAM encodes an active protease.

We next sought to determine whether PcADAMp indeed possesses protease activity. No previous studies have ever directly attributed protease activity related to a specific Pneumocystis protein. As a first approach, PcADAMp protein was heterologously expressed in S. cerevisiae, yielding a protein of predicted molecular mass 62.9 kDa, including the PcADAMp peptide (61.6 kDa) and the attached V5 epitope tag of 1.3 kDa (Fig. 6). This expressed protein reacted both with the anti-V5 and with the specific PcADAM-1 antibodies (Fig. 6). Subsequently, the yeast-expressed PcADAMp product was submitted to zymography, demonstrating proteolytic activity against casein (Fig. 7A). Furthermore, this PcADAMp protease activity was inhibited in the absence of Zn2+, indicating that this divalent cation is necessary for optimal activity, as is known for other ADAM-family metalloproteases (Fig. 7A).
In addition to further address whether PcADAMp protease activity was also present within Pneumocystis organisms, freshly isolated P. carinii were lysed, immunoprecipitated with the synthetic peptide antibodies generated to PcADAMp, and similarly submitted for zymographic analysis (Fig. 7B). Again, the native immunoprecipitated PcADAMp from Pneumocystis exhibited proteolytic activity against casein. Further, the PcADAMp proteolytic activity was largely inhibited in the presence of a comprehensive protease inhibitor cocktail (Complete Mini-Protease cocktail; Roche) (Fig. 7B). To further address the specificity of the protease activity observed in association with PcADAMp, in a parallel fashion we expressed PcCBK-1, an irrelevant protein, and examined its potential protease activity by zymography (Fig. 7C). Of note, PcCBK-1 did not exhibit any discernible protease activity, further validating the specificity of the zymographic analysis in determining the protease activity of PcADAMp. Taken together, these data indicate that PcADAMp represents a P. carinii-associated protease within the organism.

DISCUSSION

These studies strongly indicate that the opportunistic fungal pathogen P. carinii expresses PcADAM, an ADAM family molecule. Our data further indicate that PcADAM is largely expressed by cystic forms of the organism, with the related protein being localized to the surface membrane, as well as being associated with intracystic bodies within mature cysts. Our data further indicate that PcADAMp possesses protease activity, which requires the divalent cation Zn2+ for optimal function.
To date, little has been reported about the proteases of Pneumocystis. Two specific kexin family subtilisin clan serine presumptive protease genes have been partially characterized, namely, PRT1 (protease 1) and Kex1 (kexin 1) (1, 15, 20, 22, 28, 29, 43). This class of proteins has been described to function as proprotein convertases, with described roles such as the activation of peptide hormones and growth factors and the degradation of cell walls in mammals and fungi, respectively. The specific proteolytic function of the Pneumocystis PRT1 homologue has never been documented. In addition, PRT1p has been shown to possess a glycosylphosphatidylinositol derivative anchor on its carboxy terminus (34). KEX1, the other putative Pneumocystis protease described to date, has been less well characterized, and a specific function for this molecule has not been demonstrated (20, 40).
Indirect evidence of protease activity in Pneumocystis has also been previously reported (2, 4, 9, 37). However, prior to the present study, protease activity has not been attributed to a specific Pneumocystis protein. In previous studies, total Pneumocystis lysates have been demonstrated to exhibit proteolytic activity against gelatin and elastin by zymography (9). In addition, various protease inhibitors have been shown to either prevent short-term growth (leupeptin) or enhance short-term proliferation (aprotinin) of Pneumocystis organisms (3). Finally, a 68-kDa protease active against collagen, hemoglobin, and fibronectin also has been extracted from Pneumocystis and found to maximally exhibit proteolytic activity at pH 5.5. Further information suggested that the molecule may function as a cysteine protease (9).
In contrast, in the present study describes the first fully sequenced Pneumocystis protein that has now been directly documented to possess protease activity. The protease activity of PcADAMp was demonstrated using both heterologously expressed PcADAMp generated in yeast, as well as native PcADAMp purified via immunoprecipitation from fresh organisms. The protease domain present within the PcADAM gene sequence predicted homology to other proteolytically active ADAM family proteins and furthermore possessed the conserved HEXXHXXGXXHD zinc-binding catalytic site. Notably, PcADAMp zymography performed in the absence of Zn2+ failed to exhibit protease activity, as expected.
The life cycle of Pneumocystis remains poorly characterized; however, the organism is well known to interact tightly with alveolar epithelial cells, with this binding stimulating proliferation of the organism (17, 23, 25, 27). Previous studies demonstrated that when binding was inhibited by preventing direct contact of the organism with lung epithelium or by adding trimethylcolchinic acid, a binding inhibitor, the proliferation of Pneumocystis is inhibited (27). In addition, binding of the organism leads to upregulation of Pneumocystis PcSTE20 and PcMAPK expression, molecules known to signal mating and contribute to cell cycle regulation and proliferation (17).
Pneumocystis has been widely described to bind to extracellular matrix proteins, particularly fibronectin and vitronectin, promoting attachment of the organisms to lung epithelial cells (26, 35). Our group has recently reported the presence of a unique integrin molecule, PcINT1p, on the surface of Pneumocystis that mediates interactions with fibronectin (16). Pneumocystis bound extracellular matrix proteins in turn provide ligands for binding integrins on the surface of lung epithelial cells, including integrins α5, αv, β1, and α3 (36). A direct binding mechanism of Pneumocystis itself to lung epithelial cell integrins has not been previously documented.
ADAM family molecules have been demonstrated to play important roles in integrin-disintegrin binding in other species (30). However, Pneumocystis binding to lung epithelial cells has been demonstrated largely to involve the trophic form of the organism (27). We observed that PcADAMp is expressed to a far greater extent by the cystic form of the organism rather than trophic forms, suggesting that PcADAMp likely does not participate in organism-epithelial binding. Furthermore, PcADAMp contains only a partially conserved disintegrin domain. Careful scrutiny of the full PcADAMp sequence demonstrates an RGD peptide sequence proximal to the metalloprotease domain, raising the possibility of a novel proximal disintegrin function. However, we were unable to demonstrate alteration of Pneumocystis binding to cultured lung cells with the addition of custom-made antibodies to this proximal domain of PcADAMp. Specifically, anti-PcADAMp antibodies did not suppress specific Pneumocystis binding to cultured A549 lung epithelial cells (data not shown).
However, effects of PcADAMp on P. carinii life cycle regulation may involve other activities of this molecule. For instance, prior studies indicate that the PcADAM family molecule MDE10, expressed by S. pombe, is important for the development of the spore envelope, a function that is essential for completion of meiosis and which appears to be independent of the metalloprotease activity of this molecule (32). In light of our recent studies that verify the presence of a meiotic control system in P. carinii, additional investigations will be required to determine these other potential functions of PcADAMp in this organism (6-8).
In conclusion, we report here the identification, cloning, characterization, and functional activity of a novel protein PcADAMp. This is the first study to demonstrate an ADAM family member in Pneumocystis and the first to specifically identify a Pneumocystis protein demonstrating protease activity. The protein has high homology to ADM A and B from the pathogenic fungus Aspergillus and a yet-to-be-described hypothetical protein in Cryptococcus. Such ADAM family members may represent potential novel targets to better understand the life cycles, pathogenic effects, and therapeutic control of these important opportunistic fungi.
FIG. 1.
FIG. 1. Characterization of the P. carinii PcADAM coding sequence. (A) Nucleotide and predicted amino acid sequence of PcADAM derived from P. carinii genomic DNA. The forward primer for the generation of the DNA probe was 5′-CGAATCATGTAAAAATGAATCA-3′, with the primer starting at bp 1310 to 1332, and the reverse primer was 5′-CAACCTTTTTCTCCTCCACA-3′, with the primer starting at bp 1567 to 1586. (B) The PcADAM metalloprotease domain is homologous to the metalloprotease domains of other ADAM proteins.
FIG. 2.
FIG. 2. PcADAMp has high homology to other fungal ADAM proteins. (A) CLUSTAL W alignment of metalloprotease domain with Mde10 (S. pombe) and ADM B and ADM A (Aspergillus). The conserved zinc-binding catalytic site is illustrated in boldface. (B) PcADAMp has a partially conserved, homologous disintegrin domain. Diagram illustrates the partially conserved domain of Pneumocystis compared to that of Mde10 and ADM A and B.
FIG. 3.
FIG. 3. PcADAM is represented within the Pneumocystis genome. (A) Southern blot demonstrating PcADAM 276-bp probe hybridizing to restriction endonuclease-digested P. carinii genomic DNA. L, ladder. Lanes: 1, rat genomic DNA cut with EcoRI endonuclease without hybridization; 2, 3, 4, and 5, P. carinii DNA digested with the BamHI, EcoRI, HindIII, and XbaI endonucleases, respectively. The PcADAM probe hybridized to a single band under each condition. (B) CHEF blot demonstrating chromosomal localization of the PcADAM gene. The left panel shows a CHEF gel stained with ethidium bromide demonstrating chromosomal separation of Pneumocystis carinii samples obtained from a single infected rat lung. The right panel shows separated P. carinii chromosomes transferred to a nitrocellulose membrane and hybridized with a radioactive labeled PcADAM probe. The probe hybridizes to a single P. carinii chromosome, confirming presence of the PcADAM sequence within the P. carinii genome.
FIG. 4.
FIG. 4. Northern hybridization of P. carinii RNA demonstrates differential expression of PcADAM over the organism's life cycle. P. carinii organisms were separated into cyst and trophic populations, and RNA species were isolated, separated, transferred to nitrocellulose membranes, and hybridized with a radioactively labeled PcADAM probe. Multiple blots demonstrate increased expression in cyst forms of the organism compared to trophic forms. The lower panel demonstrates reprobing the membrane with a Pneumocystis actin probe to confirm equal RNA loading and integrity of the RNA used in this analysis.
FIG. 5.
FIG. 5. Electron microscopy of P. carinii forms labeled with a synthetic peptide antibody to PcADAMp. To further assess the regional distribution of PcADAMp in P. carinii, synthetic antibodies were utilized in immunoelectron microscopic studies. A representative image obtained using synthetic peptide antibody 1 to PcADAMp is shown. Cyst forms demonstrated localization of the putative PcADAMp to the cysts wall and membrane regions (arrows) and to intracystic bodies (arrowheads). In contrast, minimal if any staining was present on trophic forms (asterisks).
FIG. 6.
FIG. 6. Western blot verifies S. cerevisiae heterologous expression of Pneumocystis PcADAMp protein. Yeast were grown in 2% glucose minimal medium URA and transferred to 2% galactose minimal medium URA. The yeast cells were lysed, and protein was purified over a nickel affinity column. Yeast extracts were run on a 12% gel and transferred to nitrocellulose, and a Western blot was performed with a V5-horseradish peroxidase antibody and with the synthetic peptide PcADAM-1 antibody.
FIG. 7.
FIG. 7. PcADAMp is a selectively active protease. (A) Heterologously expressed Pneumocystis PcADAMp generated in S. cerevisiae is proteolytically active against casein. Lanes: 1, PcADAMp (4 μg, yeast expressed) with zymography performed in the presence of reactivation buffer containing Zn2+; 2, PcADAM (3 μg, yeast expressed) with zymography performed in the presence of reactivation buffer containing Zn2+; 3, PcADAM (4 μg, yeast expressed) with zymography performed in the absence of Zn2+. The yeast-expressed PcADAMp exhibits appropriate proteolytic activity as evidence by clearing of the casein impregnated gel, only in the presence of Zn2+. (B) Native P. carinii-derived PcADAMp is also proteolytically active against casein. Native PcADAMp was obtained from Pneumocystis lysate by immunoprecipitation using custom made antibodies to PcADAM. Lanes: 1, immunoprecipitation and zymography of Pneumocystis PcADAMp performed with Ab2 in the absence of protease inhibitor cocktail; 2. immunoprecipitation and zymography of Pneumocystis PcADAMp performed with Ab2 in the presence of protease inhibitors cocktail; 3, immunoprecipitation and zymography of Pneumocystis PcADAMp performed with Ab1 in the absence of protease inhibitors; 4, immunoprecipitation and zymography of Pneumocystis PcADAMp performed with Ab1 in the presence of protease inhibitors. Zymography demonstrates PcADAMp protease activity immunoprecipitated from Pneumocystis that is largely suppressed in the presence of protease inhibitors cocktail. (C) An irrelevant protein PcCBK1p does not exhibit protease activity. To further address the specificity of the protease activity observed in association with PcADAMp, we expressed PcCBK1p, the cell wall biosynthesis kinase and examined its potential protease activity by zymography. Lanes: 1, PcADAMp indicates protease activity at the appropriate molecular mass, in the absence of protease inhibitors (arrow); 2, PcCBK1p reveals no protease activity (no protease inhibitor present); 3, PcCBK1p reveals no protease activity (protease inhibitor present).

Acknowledgments

This study was funded by the Mayo Foundation and NIH grants R01-HL62150 and R01-HL55934 to A.H.L. C.C.K. was supported by institutional training grant T32-HL07897.
We are grateful to other members of the Limper laboratory for technical expertise and assistance. We also thank Charles Thomas and members of his research group for technical expertise and Margaret Springett for assistance with the immunoelectron microscopic methods and procedures. We thank Melanie Cushion for the generous gift of Pneumocystis chromosomal CHEF blot nitrocellulose membranes.

Supplemental Material

File (iai_1383_08_supplementary_figure_a.tif)
ASM does not own the copyrights to Supplemental Material that may be linked to, or accessed through, an article. The authors have granted ASM a non-exclusive, world-wide license to publish the Supplemental Material files. Please contact the corresponding author directly for reuse.

REFERENCES

1.
Ambrose, H. E., S. P. Keely, E. M. Aliouat, E. Dei-Cas, A. E. Wakefield, R. F. Miller, and J. R. Stringer.2004. Expression and complexity of the PRT1 multigene family of Pneumocystis carinii. Microbiology150:293-300.
2.
Atzori, C., E. Angeli, A. Mainini, F. Agostoni, V. Micheli, and A. Cargnel.2000. In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii. J. Infect. Dis.181:1629-1634.
3.
Atzori, C., M. Clerici, D. Trabattoni, G. Fantoni, A. Valerio, E. Tronconi, and A. Cargnel.2003. Assessment of immune reconstitution to Pneumocystis carinii in HIV-1 patients under different highly active antiretroviral therapy regimens. J. Antimicrob. Chemother.52:276-281.
4.
Atzori, C., A. Mainini, F. Agostoni, E. Angeli, M. Bartlett, A. Bruno, M. Scaglia, and A. Cargnel.1999. Detection of rat Pneumocystis carinii proteinases and elastase and antipneumocystis activity of proteinase inhibitors in vitro. Parasite6:9-16.
5.
Black, R. A., and J. M. White.1998. ADAMs: focus on the protease domain. Curr. Opin. Cell Biol.10:654-659.
6.
Burgess, J. W., T. J. Kottom, and A. H. Limper.2007. Pneumocystis carinii exhibits a conserved meiotic control pathway. Infect. Immun.76:417-425.
7.
Burgess, J. W., T. J. Kottom, and A. H. Limper.2008. Pneumocystis carinii exhibits a conserved meiotic control pathway. Infect. Immun.76:417-425.
8.
Burgess, J. W., T. J. Kottom, L. R. Villegas, J. D. Lamont, E. M. Baden, M. Ramirez-Alvarado, and A. H. Limper. 13 March 2009. The pneumocystis meiotic PCRan1p kinase exhibits unique temperature regulated activity. Am. J. Respir. Cell Mol. Biol. doi:
9.
Choi, M. H., B. S. Chung, Y. B. Chung, J. R. Yu, S. R. Cho, and S. T. Hong.2000. Purification of a 68-kDa cysteine proteinase from crude extract of Pneumocystis carinii. Korean J. Parasitol.38:159-166.
10.
Fear, G., S. Komarnytsky, and I. Raskin.2007. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol. Ther.113:354-368.
11.
Huang, L., C. B. Beard, J. Creasman, D. Levy, F. S. Duchin, S. Lee, N. J. Pieniazek, J. L. Carter, C. del Rio, D. Rimland, and T. R. Navin.2000. Sulfa or sulfone prophylaxis and geographic region predict mutations in the Pneumocystis carinii dihydropteroate synthase gene. J. Infect. Dis.182:1192-1198.
12.
Huang, L., A. Morris, A. H. Limper, and J. M. Beck.2006. An official ATS workshop summary: recent advances and future directions in pneumocystis pneumonia (PCP). Proc. Am. Thorac. Soc.3:655-664.
13.
Icenhour, C. R., S. L. Rebholz, M. S. Collins, and M. T. Cushion.2001. Early acquisition of Pneumocystis carinii in rat pups. J. Eukaryot. Microbiol.2001(Suppl.):135S-136S.
14.
Kaplan, J. E., D. L. Hanson, T. R. Navin, and J. L. Jones.1998. Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. J. Infect. Dis.178:1126-1132.
15.
Keely, S. P., and J. R. Stringer.2003. Sequence diversity of transcripts from Pneumocystis carinii gene families MSR and PRT1. J. Eukaryot. Microbiol.50(Suppl.):627-628.
16.
Kottom, T. J., C. C. Kennedy, and A. H. Limper.2008. Pneumocystis PCINT1, a molecule with integrin-like features that mediates organism adhesion to fibronectin. Mol. Microbiol.67:747-761.
17.
Kottom, T. J., J. R. Kohler, C. F. Thomas, Jr., G. R. Fink, and A. H. Limper.2003. Lung epithelial cells and extracellular matrix components induce expression of Pneumocystis carinii STE20, a gene complementing the mating and pseudohyphal growth defects of STE20 mutant yeast. Infect. Immun.71:6463-6471.
18.
Kottom, T. J., and A. H. Limper.2000. Cell wall assembly by Pneumocystis carinii: evidence for a unique gsc-1 subunit mediating β-1,3-glucan deposition. J. Biol. Chem.275:40628-40634.
19.
Kottom, T. J., and A. H. Limper.2004. Pneumocystis carinii cell wall biosynthesis kinase gene CBK1 is an environmentally responsive gene that complements cell wall defects of cbk-deficient yeast. Infect. Immun.72:4628-4636.
20.
Kutty, G., and J. A. Kovacs.2003. A single-copy gene encodes Kex1, a serine endoprotease of Pneumocystis jiroveci. Infect. Immun.71:571-574.
21.
Lavens, S. E., N. Rovira-Graells, M. Birch, and D. Tuckwell.2005. ADAMs are present in fungi: identification of two novel ADAM genes in Aspergillus fumigatus. FEMS Microbiol. Lett.248:23-30.
22.
Lee, L. H., F. Gigliotti, T. W. Wright, P. J. Simpson-Haidaris, G. A. Weinberg, and C. G. Haidaris.2000. Molecular characterization of KEX1, a kexin-like protease in mouse Pneumocystis carinii. Gene242:141-150.
23.
Limper, A. H., M. Edens, R. A. Anders, and E. B. Leof.1998. Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J. Clin. Investig.101:1148-1155.
24.
Limper, A. H., J. S. Hoyte, and J. E. Standing.1997. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J. Clin. Investig.99:2110-2117.
25.
Limper, A. H., and W. J. Martin, 2nd.1990. Pneumocystis carinii: inhibition of lung cell growth mediated by parasite attachment. J. Clin. Investig.85:391-396.
26.
Limper, A. H., J. E. Standing, O. A. Hoffman, M. Castro, and L. W. Neese.1993. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect. Immun.61:4302-4309.
27.
Limper, A. H., C. F. Thomas, Jr., R. A. Anders, and E. B. Leof.1997. Interactions of parasite and host epithelial cell cycle regulation during Pneumocystis carinii pneumonia. J. Lab. Clin. Med.130:132-138.
28.
Lugli, E. B., A. G. Allen, and A. E. Wakefield.1997. A Pneumocystis carinii multi-gene family with homology to subtilisin-like serine proteases. Microbiology143(Pt. 7):2223-2236.
29.
Lugli, E. B., E. T. Bampton, D. J. Ferguson, and A. E. Wakefield.1999. Cell surface protease PRT1 identified in the fungal pathogen Pneumocystis carinii. Mol. Microbiol.31:1723-1733.
30.
Myles, D. G., L. H. Kimmel, C. P. Blobel, J. M. White, and P. Primakoff.1994. Identification of a binding site in the disintegrin domain of fertilin required for sperm-egg fusion. Proc. Natl. Acad. Sci. USA91:4195-4198.
31.
Nahimana, A., M. Rabodonirina, G. Zanetti, I. Meneau, P. Francioli, J. Bille, and P. M. Hauser.2003. Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients. J. Infect. Dis.188:1017-1023.
32.
Nakamura, T., H. Abe, A. Hirata, and C. Shimoda.2004. ADAM family protein Mde10 is essential for development of spore envelopes in the fission yeast Schizosaccharomyces pombe. Eukaryot. Cell3:27-39.
33.
O'Riordan, D. M., J. E. Standing, K. Y. Kwon, D. Chang, E. C. Crouch, and A. H. Limper.1995. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J. Clin. Investig.95:2699-2710.
34.
Palmer, R. J., and A. E. Wakefield.2001. Functional glycosylphosphatidylinositol anchor signal sequences in the Pneumocystis carinii PRT1 protease family. Am. J. Respir. Cell Mol. Biol.25:466-473.
35.
Pottratz, S. T., and W. J. Martin, 2nd.1990. Role of fibronectin in Pneumocystis carinii attachment to cultured lung cells. J. Clin. Investig.85:351-356.
36.
Pottratz, S. T., and A. L. Weir.1997. Gamma-interferon inhibits Pneumocystis carinii attachment to lung cells by decreasing expression of lung cell-surface integrins. Eur. J. Clin. Investig.27:17-22.
37.
Russian, D. A., V. Andrawis-Sorial, M. P. Goheen, J. C. Edman, P. Vogel, R. E. Turner, D. L. Klivington, C. W. Angus, and J. A. Kovacs.1999. Characterization of a multicopy family of genes encoding a surface-expressed serine endoprotease in rat Pneumocystis carinii. Proc. Assoc. Am. Physicians111:347-356.
38.
Schwettmann, L., and H. Tschesche.2001. Cloning and expression in Pichia pastoris of metalloprotease domain of ADAM 9 catalytically active against fibronectin. Protein Expr. Purif.21:65-70.
39.
Sloand, E., B. Laughon, M. Armstrong, M. S. Bartlett, W. Blumenfeld, M. Cushion, A. Kalica, J. A. Kovacs, W. Martin, E. Pitt, et al.1993. The challenge of Pneumocystis carinii culture. J. Eukaryot. Microbiol.40:188-195.
40.
Stringer, J. R., and M. T. Cushion.1998. The genome of Pneumocystis carinii. FEMS Immunol. Med. Microbiol.22:15-26.
41.
Thomas, C. F., R. A. Anders, M. P. Gustafson, E. B. Leof, and A. H. Limper.1998. Pneumocystis carinii contains a functional cell-division-cycle Cdc2 homologue. Am. J. Respir. Cell Mol. Biol.18:297-306.
42.
Thomas, C. F., Jr., and A. H. Limper.2004. Pneumocystis pneumonia. N. Engl. J. Med.350:2487-2498.
43.
Wells, J., C. G. Haidaris, T. W. Wright, and F. Gigliotti.2006. Active immunization against Pneumocystis carinii with a recombinant P. carinii antigen. Infect. Immun.74:2446-2448.
44.
White, J. M.2003. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol.15:598-606.

Information & Contributors

Information

Published In

cover image Infection and Immunity
Infection and Immunity
Volume 77Number 8August 2009
Pages: 3328 - 3336
PubMed: 19451239

History

Received: 12 November 2008
Revision received: 17 December 2008
Accepted: 9 May 2009
Published online: 1 August 2009

Permissions

Request permissions for this article.

Contributors

Authors

Cassie C. Kennedy
Thoracic Diseases Research Unit, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
Theodore J. Kottom
Thoracic Diseases Research Unit, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
Andrew H. Limper [email protected]
Thoracic Diseases Research Unit, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905

Notes

Supplemental material for this article may be found at http://iai.asm.org/.
Editor: A. Casadevall

Metrics & Citations

Metrics

VIEW ALL METRICS

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

View Options

View options

PDF

Download PDF

Full Text

Open Full Text

ePub

Open ePub

Get Access

Buy Article
Infection and Immunity Vol.77 • Issue 8 • ASM Journals Pay Per View, PPV 25
Journal Subscription
Infection and Immunity
ASM members can purchase subscriptions to journals.
Join or renew

Figures and Media

Figures

Media

Tables

Share

Share

Share the article link

Share with email

Share on social media

American Society for Microbiology ("ASM") is committed to maintaining your confidence and trust with respect to the information we collect from you on websites owned and operated by ASM ("ASM Web Sites") and other sources. This Privacy Policy sets forth the information we collect about you, how we use this information and the choices you have about how we use such information.
FIND OUT MORE about the privacy policy